Thermo Fisher Scientific Inc.

NYSE:TMO  
596.61
+36.17 (+6.45%)
Products

Takeda Pharmaceutical Co's Exkivity(Mobocertinib) Approved By U.S. FDA As The First Oral Therapy Specifically Designed For Patients With Egfr Exon20 Insertion+ Nsclc

Published: 09/15/2021 21:55 GMT
Thermo Fisher Scientific Inc. (TMO) - Takeda’s Exkivity™ (mobocertinib) Approved by U.S. FDA As the First Oral Therapy Specifically Designed for Patients With Egfr Exon20 Insertion+ Nsclc.
Takeda Pharmaceutical Co - Indication is Approved Under Accelerated Approval Based on Overall Response Rate (orr) and Dor.
Takeda Pharmaceutical - Exkivity Prescribing Information Includes a Boxed Warning for Qtc Prolongation and Torsades De Pointes.
Takeda - FDA Approved Thermo Fisher Scientific's Oncomine Dx Target Test.
Takeda Pharmaceutical - Exkivity Prescribing Information Also Includes Warnings for Interstitial Lung Disease/pneumonitis, Cardiac Toxicity, Diarrhea.
Takeda - FDA Approved Oncomine Dx Target Test As an Ngs Companion Diagnostic for Exkivity to Identify Nsclc Patients With Egfr Exon20 Insertions.